Webdisclosure.com

Search

SANOFI-AVENTIS (EPA:SAN) Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis

Directive transparence : information réglementée

14/07/2022 07:00